About

Michael Mastromauro is associated with the College of Veterinary Medicine at NC State University, where he is involved in fostering student engagement and supporting the academic community. His role includes overseeing student experience initiatives, promoting a collaborative and inclusive culture, and facilitating opportunities for students to grow both personally and professionally. His work emphasizes the importance of student achievement, well-being, and the development of future veterinary professionals through various programs and support services.

Research topics

• Medicine
• Pathology
• Political Science
• Internal medicine
• Library science
• Family medicine
• Gerontology
• Environmental health
• Veterinary medicine
• Surgery
• Oncology

Selected publications

• 855 Interim results from a comparative oncology safety study evaluating intravesical chitosan/interleukin-12 immunotherapy in client-owned dogs with invasive urothelial carcinoma

  Regular and Young Investigator Award Abstracts · 2025-11-01

  articleOpen access

  Table 1 Adverse events following intravesical chitosan/interleukin-12 immunotherapy in client-owned dogs with invasive urothelial carcinoma

  PublisherOA PDFDOI

• Pathology in Practice

  Journal of the American Veterinary Medical Association · 2022

  • Medicine
  • Pathology
  PublisherDOI

• Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003–2017)

  Journal of the American Veterinary Medical Association · 2022 · 12 citations

  • Medicine
  • Internal medicine
  • Surgery

  OBJECTIVE: To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy. ANIMALS: 31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017. PROCEDURES: Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests. RESULTS: The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy. CLINICAL RELEVANCE: Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens.

  PublisherOA PDFDOI

• Pathology in Practice

  Journal of the American Veterinary Medical Association · 2022-05-18

  article

  In collaboration with the American College of Veterinary Pathologists.

  PublisherDOI

• What is your diagnosis? Dermal mass in a dog

  Veterinary Clinical Pathology · 2021 · 1 citations

  • Political Science
  • Library science
  • Medicine
  PublisherDOI

• What is your diagnosis? Lymphocytes engulfing erythrocytes in a cat

  Veterinary Clinical Pathology · 2019-06-28 · 2 citations

  article
  PublisherDOI

• Well-differentiated papillary mesothelioma of the tunica vaginalis: Case report and literature review

  Urology Case Reports · 2018-10-05 · 5 citations

  articleOpen access
  PublisherDOI

• Oral melphalan for the treatment of relapsed canine lymphoma

  Veterinary and Comparative Oncology · 2017-09-21 · 7 citations

  article1st authorCorresponding

  Oral melphalan has been included in multi‐agent rescue protocols for canine lymphoma but its activity as a single‐agent for this purpose has not been established. Inexpensive cost, ease of administration and tolerability make oral melphalan an attractive candidate for single‐agent rescue therapy of canine lymphoma. Retrospective evaluation of 19 cases of relapsed canine lymphoma treated with oral melphalan was performed. Melphalan was primarily administered ( n = 16) via a high dose protocol ( HDM ) with a median dosage of 19.4 mg m −2 . Fifteen dogs (78.9%) were treated concurrently with corticosteroids. Response evaluation was possible for all dogs with a calculated overall clinical benefit (partial response [ PR ] + stable disease [ SD ]) of 31.6% ( PR 3/19; SD 3/19). Times to progression following melphalan ( TTP ‐M) were 14, 24 and 34 days for responders and 20, 28 and 103 days for dogs experiencing SD . Twelve of 17 dogs evaluable for toxicity experienced an adverse event ( AE ) with only 3 dogs experiencing a grade III or higher AE . Haematologic toxicity was common (11/17) while gastrointestinal toxicity was rare (1/17). Although treatment resulted in limited clinical benefit and non‐durable responses, oral melphalan was well‐tolerated and may be a reasonable rescue option in cases where minimal effective agents remain.

  PublisherDOI

• Acquired myasthenia gravis in a German Shepherd dog

  eCommons (Cornell University) · 2011-10-26

  article1st authorCorresponding

  A five-year old male castrated German Shepherd dog, presented to the Cornell University Hospital for Animals (CUHA) Emergency Service on September 11th, 2011 for hindlimb paresis and aspiration pneumonia. On initial assessment, the patient exhibited tetraparesis that worsened with activity. Repeat thoracic radiographs showed persistence of previously diagnosed megaesophagus and aspiration pneumonia. The patient was hospitalized and started on IV fluids and antibiotics and transferred to the Internal Medicine Service the next day. A Tensilon test was performed which was positive and treatment was initiated with pyridostigmine, dexamethasone, and mycophenolate mofetil for presumptive acquire myasthenia gravis. Anti-acetylcholine receptor antibody titers were submitted but the patient was deemed seronegative. Over the next 3 days, the patient improved and was discharged with near complete resolution of both the megesophagus and aspiration pneumonia. Using the above case as an example, the pathophysiology of acquired myasthenia gravis with a focus on diagnostic and treatment options will be discussed.

  Publisher

• CS.3.7 COST-EFFECTIVENESS OF MEDICAL COUNSELLING IN FAECAL OCCULT BLOOD-POSITIVE SUBJECTS. EXPERIENCE OF TRENTINO SCREENING PROGRAM

  Digestive and Liver Disease · 2010-03-01 · 1 citations

  article
  PublisherDOI

Frequent coauthors

• E. Ntakirutimana

  3 shared

• L. Benazzato

  Azienda ULSS 9 TREVISO

  3 shared

• P. Inturri

  3 shared

• Hiroyuki Mochizuki

  North Carolina State University

  2 shared

• Amanda Ederle

  Baptist Health Foundation

  2 shared

• T. Draghici

  Spitalul Clinic Colentina

  2 shared

• Devorah M. Stowe

  North Carolina State University

  2 shared

• B. Brenseke

  Campbell University

  2 shared

Awards & honors

• Diplomate, American College of Veterinary Internal Medicine…
• American College of Veterinary Internal Medicine
• Veterinary Cancer Society